Arthneeti
Sale is live|00:00:00
Aimco Pesticides LtdQ3 FY25

Aimco Pesticides Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 55.1Market Cap: ₹57 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • Target revenue for FY26: Over ₹210 crore (Ashit Dave on Q4 and FY26 outlook).
  • Brand business revenue target for FY26: ₹200 crore (aim to double in two years).
  • Volume growth expectation: 15-20% increase year-on-year.
  • Export to domestic sales ratio currently ~50:50, with expectation of export business improvement in FY26.
  • New products: Three recently commercialized molecules expected to generate significant revenue from next financial year.
  • Capacity utilization: Currently around 70%, with plans to repurpose insecticide plant and consider additional capacity in Q4 FY25.
  • Bifenthrin capacity to be fully utilized in next two financial years, driven by Brazil market entry.
  • Overall growth dependent on pricing, market conditions, and regulatory registrations, especially in Brazil.
  • EBITDA margin expected to remain stable or improve with new high-margin branded products.

Margin guidance

Category 3
  • Aimco Pesticides expects to be profitable by the end of FY25, with improving Q3 and Q4 performance.
  • Revenue target for FY25 is over ₹210 crore, with EBITDA margins expected to improve, though Q4 pricing remains uncertain.
  • For FY26, a clearer revenue and EBITDA margin target will be shared next quarter; branded business aims for ₹200 crore revenue by FY26.
  • The company plans 15-20% volume growth annually over the next couple of years, aided by new product launches and export market expansion.
  • Gross margins for branded formulations are stable at 30-35%, with EBITDA margins around 10%, expected to sustain as product mix improves.
  • New products commercial ramp-up and export registrations (e.g., Triclopyr in Brazil in FY26) should enhance growth.
  • Capex remains cautious to preserve cash flow, focusing on repurposing existing plants for new products with major capacity expansions deferred till profitability stabilizes.

3 more insights locked — sign up free to unlock

Fundraise plans

  • Currently, there is no mention of any ongoing or planned fundraising through debt or equity.
  • The company has put major Capex plans on hold to avoid burdening cash flow during difficult times.
  • Future Capex decisions, including investments in additional manufacturing capacity, will be taken cautiously after stabilizing profitability and margins.
  • Any large investments or capacity expansions will be evaluated and decided by the board at appropriate times.
  • No specific plans for raising funds via equity or debt have been disclosed for FY25 or FY26.

Order book

  • Significant orders are ongoing in Q3, with volume-wise expectations being satisfactory.
  • Q4 order projections are uncertain due to pricing and supply issues, especially from China.
  • Negotiations for new export contract products, including a herbicide, are ongoing but not finalized.
  • Discussions for Bifenthrin volumes in Brazil are active, expecting significant volume in Q4 and full capacity utilization by FY26.
  • Three new products are commercialized and early stage sales have started; significant ramp-up expected in next financial year.
  • The company's export orderbook faces pressure from price erosion and competition but volume remains steady.
  • Domestic brand business order momentum is strong and growing with expected revenue of ₹130 crore for FY25 and ₹200 crore by FY26.
  • Additional capacity decisions for new molecules pending and to be finalized next quarter.

Capex plans

Yes
  • Current Capex is on hold to avoid burdening cash flow during difficult times; focus is on stabilizing existing business first.
  • Planned Capex for FY25 includes ₹1.5 to 2 crores to repurpose existing manufacturing facilities for a new product (modification and debottlenecking).
  • Major Capex proposals (formulation plant and intermediate plant with ~2000 tons capacity) have been deferred to FY26 or beyond, pending profitability and margin improvement.
  • Two new formulation plants have been acquired; setting up of a new formulation plant expected next year to add capacity, not to shift existing plant.
  • Additional capacity decisions for three new molecules will be made in Q4 FY25 based on market conditions.
  • Large-scale capacity expansions for new products anticipated in FY26 after product registrations and market demand improve.
  • Board to evaluate and approve any major future plant capacity investments carefully.

How does Aimco Pesticides Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature
1Aimco Pesticides Ltd
Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings